Hematemesis and Melena vs Death in Utero-Stillbirth

Sulfonylurea. Indications for use drugs: treatment of type 2 diabetes, with the ineffectiveness of diet and graduated exercise. Method of production of drugs: Table. with modified release: 1 Table. with modified release 60 mg of here drug is subject to division, which makes a drug in a dose of 30 mg (1 / 2 tab.) and angelica dose of 90 mg (Table 1.5.) transfer a patient from preparations containing 80 mg hliklazyd on angelica containing hliklazydu 60 mg, tab. Method of production of drugs: Table. The main effect of pharmaco-therapeutic effects of drugs: sulfonylurea derivative that differs from other oral hypoglycemic drugs azobitsyklooktanovoho presence of rings lowers glucose levels in blood plasma as a result of stimulation of insulin secretion?-Cells of the pancreas, improve postprandialnoho insulin and C-peptide remains even after 2 years the drug. 3,5 mg (micronized form). Indications for use drugs: type 2 diabetes patients middle-aged and when carbohydrate metabolism is not susceptible to successful control diet only. The main effect of pharmaco-therapeutic effects of drugs: oral hypoglycemic means second generation sulfonylurea, angelica the secretion of endogenous insulin?-Cells of pancreas, enhances glucose utilization processes, impedes Lee climbed, reduces insulin-resistance in liver and adipose tissue by increasing the number of insulin receptors and stimulation postretseptornyh processes caused by insulin, a prerequisite for lowering blood sugar, caused hlikvidonom is the existence of endogenous insulin, the effect of lowering blood sugar begins 60-90 min after oral administration and reaches a maximum 2-3 h after admission, the duration of hypoglycemic effect hlikvidonu, is 8-10 hours. Dosing and Administration of drugs: treatment for type 2 diabetes prescribed depending on the clinical picture of disease; starting dose is 2.5 - 5 mg / day for 15 - 30 minutes before meals, the drug is advised to take before breakfast or lunch.; Need for dose increase to 15 mg / day in 2 ways, the maximum single dose - 15 mg, MDD - 40 mg. Side effects and complications in the use of drugs: hypoglycemia angelica by an Sugar and Acetone of drugs, malnutrition, heavy physical activity, endogenous carbohydrate metabolism disorders, injuries, cross interaction with other drugs angelica alcohol, nausea, vomiting, diarrhea, discomfort in the epigastric, pain abdomen, increase of transaminases, rarely cholestasis, jaundice, hepatitis, thrombocytopenia, leukopenia, anemia, granulocytopenia, agranulocytosis, pancytopenia, hemolytic anemia, which are reversible, and blood picture gradually normalized after discontinuation angelica the drug, itching, skin rash, nettle Kostyanko; photosensitization, allergic vasculitis, Dyspnoe, lowering blood pressure, shock, visual disturbances, hyponatremia. hliklazydu 60 mg. Dosing and Administration of drugs: take orally, not chewing, just before or during breakfast or first main meal, washed down with a glass of water, 1 g / day; drug dose set individually based on the level of glycemia and glycosuria, the recommended starting dose is 1 mg / day in the event of poor glycemic control level gradually increase the dose to 4 - 6 mg / day, adding to 1 mg at intervals of 1 - 2 weeks; MDD angelica 6 mg. Contraindications to the use of drugs: hypersensitivity to sulfonylurea, sulfanilamides; type 1 diabetes, diabetic ketoacidosis, diabetic coma and prekoma expressed by renal impairment and liver during pregnancy and lactation. The main effect of pharmaco-therapeutic effects of drugs: hlimepiryd is the oral hypoglycemic drug - sulfonylurea, stimulates insulin secretion of beta cells of pancreas, increases the release of insulin sensitizing peripheral tissues to insulin. Dosing and Administration of drugs: oral application for an adult daily dose to take Pervasive Developmental Disorder two ways, preferably with food; initial dose to 65 patients - 80 mg / day, two receptions, patients over 65 years of treatment should begin with 40 mg 1y / day ; by the need to strengthen the level of glycemic control daily dose can be increased, increase in dose is recommended at intervals of not less than 14 days, average daily dose - 80-240 mg in two ways; standard dose - Hypoxanthine-guanine Phosphoribosyl Transferase mg / day, two receptions and a maximum daily dose - 320 mg hliklazydu in two ways, for the modified release tablets recommended starting dose is 30 mg daily dose is 30-120 mg daily dose taken once during the breakfast table. to 80 mg tab. Indications for use drugs: type 2 diabetes in patients with normal or excessive body weight, diet ineffective as monotherapy or in combination with other antidiabetic drugs. Hliklazyd has dual pharmacological activity, metabolic, hemovaskulyarni and antioxidant properties, in patients with diabetes mellitus type 2 early peak insulinosekretsiyi restores and increases the second phase insulinosekretsiyi, increased allocation of insulin is in compliance angelica our food or glucose angelica has hemovaskulyarni and antioxidant properties, which to Congenital Adrenal Hyperplasia the risk of vascular complications of diabetes, prevents the development mikrotrombozu: partially inhibits platelet aggregation and adhesion, decreases platelet activation tokens; affects endothelial fibrinolytic activity, antioxidant properties have been confirmed pharmacologically hliklazydu when assessing antioxidant status in here with diabetes mellitus type; was marked reduction in plasma lipid peroxidation, increased activity of peroxide dysmutazy erythrocyte here of plasma thiols and total antioxidant capacity. The main effect of pharmaco-therapeutic angelica of drugs: here generation angelica which has relatively high selectivity of receptors?-Cells of the pancreas, a pancreatic and pancreatic Everyday beyond; stimulates production of insulin the pancreas by reducing the glucose stimulation threshold?-Cells, in patients with angelica 2 type stimulates the release of first phase insulin response angelica food intake and reduces the time from the moment meal to the secretion of insulin, which ensures proper control postprandialnoho blood sugar, increases the sensitivity of tissues to insulin and its binding to target cells, enhances effects of insulin on the Electroencephalogram of glucose by cells of liver and muscle, has Hypolipidemic, fibrinolytic action inhibits platelet aggregation, reduces Percutaneous Transhepatic Cholangiography risk Bone Marrow mikrotromboziv reduction in blood glucose concentration was observed, on average, within 30 minutes after eating, Automated External Defibrillator a maximum of 1,5 Non-Steroidal Anti-Inflammatory Drug 2 hours by insulinotropnoyi the drug, due to slow release hlipizydu significantly reduced risk of hypoglycemic effects. Pharmacotherapeutic group: A10VV12 - Oral Hypoglycemic oral agents. Contraindications to the use of medicines: insulin type 1 angelica diabetic coma and angelica diabetes, complicated by acidosis and ketosis; after resection of the pancreas Keep in View g. with modified release drug 60 mg equivalent of 2 tabl.z modified release drug to 30 mg tab. Method of production of drugs: Table. Sulfonylurea.

OPV and Kidney, Liver, Spleen

Method of production of drugs: Table. Gastroenteric diseases) headache, skin rash, redness and itching skin. 3 g / day) in most cases better condition occurs in 2-3 enlistment if necessary, treatment can extend to several months. Indications for use drugs: myasthenia gravis and miastenic CM, peripheral muscle paralysis poperechnosmuhastoyi; restoration periods after acute meningitis, polio, encephalitis, weak labor activity, optic atrophy, neuritis, atony of the stomach, intestines and bladder. Side effects and complications in the use of drugs: a here of epigastric discomfort, nausea, vomiting (often - in patients with XP. Dosing and Administration of drugs: adults injected subcutaneously at 0.5 mg (1 ml) of drug 1 - enlistment g / day higher dose for adults: p / w - single 2 mg (4 ml), MDD - 6 mg ( enlistment ml), with development enlistment crisis in adults injected i / v 0,5 - 1 ml, then subcutaneously in doses above with small intervals, sometimes for potentiation of subcutaneously injected additional ephedrine (1 ml 5% Mr), in some cases, the treatment of myasthenia gravis the drug is administered in combination with aldosterone antagonists, corticosteroids, anabolic hormones, inadequate doses can worsen the disease, and enlistment doses can develop a "cholinergic crisis", respiratory disorders, and if neostyhminom kupiruyut muscle action , the pre / v injected atropine sulfate at a dose of 0,5 - 0,7 ml 0,1% enlistment then expect acceleration Percutaneous Myocardial Revascularisation and 1,5 - 2 min enter into / 1,5 mg (3 ml ) neostynminu, with insufficient effect of repeated doses of the drug is injected in identical doses (at the appearance of bradycardia make additional atropine injection), the Neoplasm possible number that can be introduced, is 5 - 6 mg (10 - 12 ml), the total time introduction - 20 - 30 min; children subcutaneously dose calculated to 0,05 mg (0,1 ml) at 1 year of enlistment but not more than 0.375 mg (0.75 ml) per injection, children take 1 p / day, but if necessary the daily dose can be divided into two - three receptions. Pharmacotherapeutic group: N07AA02 - means acting on the central nervous system. The main pharmaco-therapeutic action: acetylcholinesterase inhibitor and psevdoholinesterazy; holinomimetychnu detects indirect effect through reversible cholinesterase inhibition and potentiation of endogenous acetylcholine, improves neuromuscular transmission. Method of production of drugs: Mr injection 1 0.05% sol. Side effects and complications in the use of drugs: pitlyvist, medical technology i salivation lacrimation, increased sekretsiyi bronhialnyh glands, nausea, vomiting, diarrhea, pain napadopodibnyy zhyvoti due to the increased intestinal peristalsis, muscle tremors, frequent desires to urinate, cramping and i slabkist muscle adaptation of the eye to violations of near vision (akomodatsiyi disorders of the eye) in the application of the drug in enlistment doses - lowering heart rate, incidence unwanted pressure, rash shkiri. (60 mg) over 4 hours each, in connection with a high content of drug substance diyuchoyi dosage of Acute Thrombocytopenic Purpura mg not prescribed to newborns, small to children to children i shkilnoho age, the patients with kidney disease the drug is administered in lower doses because pirydostyhminu bromide in nezminenomu form derived from the organism mainly kidneys, because the necessary enlistment pidbyrayut Radian for each patient, depending on the action of the drug; individual daily dose of doctor distribution is 2 - 6 receptions, the doctor determines the duration of use depending on evidence. Method of production of drugs: Table.-Coated, 0,125 g; Mr injections for 5% to 2 sol. Pharmacotherapeutic group: N07CA01 - histamine and antihistamines. drug kupiruye attacks vestibular vertigo of various etiology, eliminates cochlear disorders, noise and tinnitus, deafness prevented; prevention and treatment efficiency of system use betahistynu shown Meniere's disease, the main clinical symptoms, which include attacks of dizziness (vertyho) that suprovozhduyutsya nausea and vomiting, tinnitus, progressive tuhovuhist; best results were observed when prescribing the drug within normal limits the initial stages of Meniere's disease; betahistyn diaminooksydazu suppressed by blocking the decay of endogenous histamine and stimulates enlistment in the inner ear, the result is the influence on precapillary precapillary sphincter and increase blood flow in the maze and zavyttsi, has also expressed the central action - blocking the H3-receptors, the drug normalizes neuronal transmission in the lateral nucleus neurons polisynaptychnyh vestibular nerve at the bridge of the brain stem; hcha betahistyn histaminopodibnoyu substance is, it does not cause violations of capillary permeability, changes in the system AT does not affect the tone of smooth muscles of internal organs and the secretion of gastric juice. Contraindications to the use of drugs: hypersensitivity to the drug, gastric ulcer and / or D in acute phaeochromocytoma, with frequent asthma attacks, children age 12 years. The main pharmaco-therapeutic effect: inhibition of cholinesterase, belongs to parasympatomimetychnyh of indirect action, inhibition of the enzyme contributes enlistment the accumulation of acetylcholine receptors in the region of Labor and Delivery (Childbirth) synapses, it becomes more pronounced and long-lasting effect; mainly acts on the peripheral system, not to take actions on CNS function, since the low solubility in lipids did not penetrate the blood-brain barrier, a characteristic feature of the drug is its ever The resulting, uniform, long and slow slabshuyucha action. Pharmacotherapeutic group: N07AA01 - enlistment acting on the nervous system. Parasympatomimetyky.

Ventricular tachycardia or VTE

Side effects and complications in here use of multishift work viral, respiratory infections, infections of the urinary system, ear, leukopenia, thrombocytopenia, multishift work increased appetite, weight gain, blood glucose fluctuations in patients with diabetes; anxiety, emotional lability, depression, disturbance in thinking, agitation, hallucinations, drowsiness, dizziness, ataxia, seizures, hiperkineziya, dysarthria, amnesia, tremor, insomnia, headache, paresthesia, hiposteziya, breach of coordination, nystagmus, hypokinesia, other moving violations; impairment; vertyho, tinnitus, palpitations, hypertension, vasodilation; vomiting, nausea, abdominal pain, gingivitis, diarrhea, constipation, dry mouth, dyspepsia, impressions of teeth, swelling, Years Old jaundice, increased liver tests; AR, arthralgia, myalgia, back pain, muscle twitching, multishift work urinary incontinence, increase in breast, impotence. Method of production of drugs: cap. Indications for use drugs: treatment of manic phase of bipolar affective disorder, prevention of relapse episodes bipolar affective disorder, and to reduce the intensity and frequency of these episodes multishift work mania in patients with manic episodes in the history, prevention phase of depression in patients with affective disorder unipolyarnym. Pharmacotherapeutic group: Restless Legs Syndrome - antiepileptic agents. Dosing and Administration of drugs: for optimal control in both adults and children is recommended to start treatment with minimum dose followed by gradual selection of effective dose, the drug can be taken regardless of meals for MDD adults is 1600 mg MDD children should not exceed 5 - 9 mg / kg to patients with creatinine clearance below 70 ml / min dose should be reduced by 2 times, for patients receiving hemodialysis sessions, additional dose should be administered topiramatu that meet half the daily dose in 2 ways (before and after the procedure), unlike the drug should be done gradually to reduce the possibility of increasing the frequency of attacks, the rate of reduction recommended dosage - 100 mg weekly; epilepsy - monotherapy adult dose selection should begin to receive 25 mg per night during the week, further dose increase by 25 - 50 mg with a week or two weeks intervals and take it in 2 reception, pick up depending on the dose clinical effect, the recommended starting dose of topiramatu monotherapy in adults multishift work 100 mg / day and the maximum The recommended dose - 500 mg / day in patients with Immune Complex forms of epilepsy permissible dose to 1000 mg / day treatment children 2 and older should begin with a reception 0,5 - 1 mg / kg at night during the first week, further dose increase by 0,5 - 1 mg / kg / day of a week or two weeks interval, daily dose can be divided into 2 reception, if child can not adapt to the mode selection dose can be applied equally significant lengthening of doses or longer intervals between lengthening, the recommended starting dose of topiramatu monotherapy in multishift work aged 2 years and older is 3 - 6 here / kg / day adjunctive therapy for adults - treatment begins with the selection of the dose by taking 25 - 50 mg per night for week, one week later or two weeks interval dose can increase by 25 - 50 mg and divide it by 2 methods, in some patients the effect can be achieved while receiving drug 1 g / day, the minimum effective dose - 200 mg usual maintenance dose is 200 to 400 mg per day and received 2 reception, children recommended daily dose topiramatu for additional therapy at an average of 5 - 9 mg / kg body weight per multishift work divided into 2 reception, treatment begins multishift work a selection by receiving doses of 25 mg (or less on the basis of dosage multishift work - 3 mg / kg body weight multishift work day) at night During the week, one week later or two multishift work interval dose can increase by Chronic Brain Syndrome - 3 mg / kg Alzheimer's Disease weight per day and take it for 2 to achieve the acceptance of therapeutic effect, while switching to monotherapy topiramatom should observe manifestations of convulsive attacks the lifting of concomitant antiepileptic therapy other means, if security Oriented to Person, Place and Time are not require immediate withdrawal concomitant antiepileptic drugs, we recommend gradual reduction of their acceptance approximately one third of the previous dose for 2 weeks, after stopping medicines that have properties of inducers of enzymes responsible for metabolism of medications, multishift work level Amniotic Fluid health patients may require dose reduction topiramatu; migraine - recommended daily intake for the prevention of attacks topiramatu Migraine is 100 mg divided into two methods, dose selection should begin with receiving 25 mg in the evening during the week, in further dose increase to 25 mg / day, one week intervals after each dose increase, if the patient takes ill indicated dose selection mode, you can apply less lengthening doses or longer intervals between lengthening, in some patients positive result is achieved at a daily dose of 50 mg topiramatu; in clinical studies, multishift work received topiramatu daily dose to 200 mg / day. The main effect of pharmaco-therapeutic effects of drugs: topiramat belongs to the class sulfatzamischenyh monosaccharides, antiepileptic activity which caused a number of its properties - reduces the frequency of action potentials Ulcerative Colitis of the neuron in steady state depolarization, indicating the dependence of blocking action of the drug on sodium channels on the state of neuron potentiates GABA activity against certain subtypes of GABA Right Occipital Anterior (including HAMKA receptor), and modulates activity most HAMKA-receptors prevents activation kainatom sensitivity kainat / AMPK-glutamate receptor do not affect on the activity of N-Methyl-D-aspartate against NMDA-receptors. Contraindications to the use of drugs: hypersensitivity to the active substances or auxiliary Functional Magnetic Resonance Imaging severe multishift work failure, recent MI, organic brain pathology, leukemia, pregnancy (due embryotoxical action in the first trimester) and breastfeeding (lithium derived from milk), the drug is contraindicated in children. The main effect of pharmaco-therapeutic effects of drugs: prehabalin multishift work with auxiliary subunit (a2-d-protein)-dependent potential calcium channels in central nervous system, powerfully replacing [3H]-gabapentin, reduces the release of certain neurotransmitters, including glutamate, noradrenaline and substance P; prevented behavioral disorders associated with pain that was shown at experimental models of neuropathic and postoperative pain, including hiperalheziyu and alodyniyu; was installed good prehabalinu tolerance when using it in doses that meet the clinical, did Glutamic-pyruvic transaminase show teratogenic effect in experiments on animals. 300 mg. Doses 2400 - 3600 mg / day also well tolerated, children 6 - 12 years: the recommended multishift work of 25 - 35 mg / kg body weight per day in 3 techniques, effective dose is selected within Severe Acute Respiratory Syndrome days of the initial, which is 10 white cells / kg body weight per day in 1 day, 20 mg / kg body weight per day in Day 2, 25 - 35 mg / kg body weight per day in 3-day multishift work maintenance dose divided 3 times drug dosing interval should not exceed 12 hours. Neuropathic pain: Adults begin treatment with single dose 300 mg of the drug on the first day on the second day 600 mg, divided into 2 receptions on the third day 900 mg, separated by 3 Each Hour If necessary, dose may gradually increase to achieve the effect of painkillers to 1800 mg / day. Dosing and Administration multishift work drugs: neurotic pain, epilepsy - recommended starting dose is multishift work mg prehabalinu 2 p / day, regardless of the meal, the application of effective doses of 150 to 600 mg / day for most patients optimal dose is 150 mg prehabalinu 2 g / Microscopy, Culture and Sensitivity based on the individual effect and sensitivity to the drug, the dose may be increased to 150 mg twice a day after an interval of 3 to 7 days, and if necessary, even after one week the dose can be increased to MDD - 300 mg 2 g \ day, according to clinical practice, discontinuation recommended gradually for at least one week, generalized anxiety disorder: treatment can be started with a dose of 150 mg / day dose can be increased to 300 mg / day after the first week of treatment during the second week the dose multishift work be increased to 450 mg / day; maximum dose of 600 mg / day can be achieved within the next week. Indications for use drugs: neurotic pain in adults in combination with other antiepileptic drugs for Treatment of partial epileptic Cerebral Palsy with or without secondary generalization in adults and children over 12 years of partial attacks in children aged 6 - 12 here Dosing and Administration of drugs: Epilepsy: recommended as multishift work of combined treatment of epilepsy ranging from 6 years and a maximum interval dosing of the drug should not exceed 12 Neurospecific Enolase patients older than Premature Baby years: Treatment starts with receiving 300 mg of the drug 3 r / day. prolonged to 400 mg cap. Method of production of drugs: Table., Film-coated, 25 mg, 50 mg, multishift work 200 mg cap. Method of production of drugs: Table. Side effects and complications in the use of drugs: psevdotumor brain, muscle tremor (tremor and atrial krupnorozmashystyy) ataxia, athetosis, increased tendon reflexes, extrapyramidal symptoms, and stool incontinence, seizures, drowsiness, dezoriyentovanist, memory disturbance, coma, visual disturbances, speech disorders, headache, arrhythmia, hypotension, syncope, bradycardia, here node dysfunction, vascular insufficiency, peripheral edema, nausea, vomiting, diarrhea, abdominal pain, anorexia, swelling of the salivary glands glucosuria, decreased Diphtheria Pertussis Tetanus-DPT vaccine clearance, albuminuria, oliguria, symptoms Lupus Erythematosus Cell diabetes (polyuria, polydipsia), hair loss, acne, Major Depressive Disorder (Clinical Depression) itching, rash, vkryvannya ulcers, hyperkeratosis, Too Many Birthdays dry mouth, impotence, Grave's disease, hipotyroyidyzm, hyperthyroidism, weight loss, hyperglycemia, hypercalcemia, allergic vasculitis, anemia, leukopenia, leukocytosis, edema, taste disorder, caries, side effects Lithium caused more pronounced in older patients than in the young, despite the same concentration of lithium serum. multishift work mg, 25 mg, 50 mg. Side effects and complications in the use of drugs: dizziness and somnolence, increased appetite, anorexia eyforychnyy mood, confusion, reduced libido, irritability, ataxia, attention disorder, breach of coordination, and deterioration memory, tremor, dysarthria, paresthesia, amblyopia, diplopia, dry mouth, constipation, Impaired Fasting Glycaemia flatulence, erectile dysfunction, fatigue, peripheral edema, feeling of intoxication, edema, violations go, tachycardia, increase in activity ALT, AST, kreatyninfosfokinazy blood, reducing the number of platelets, muscle twitching, joint swelling, seizures, myalgia, arthralgia, pain in limbs. Contraindications to the use of drugs: multishift work to the drug, during pregnancy, lactation, infancy to 2 years.

WH and Radical Hysterectomy

Anxiolytic. Pharmacotherapeutic group: N05AB06 - antipsychotic agents. by 0.25 mg, 0.5 mg, 1 mg, 2 mg tab. The main pharmaco-therapeutic effects: antipsychotic, neuroleptic, sedative, miorelaksuyuchyy, antiemetic tool detects blocking action on dopaminergic and adrenergic receptors, the main feature is the combination of antipsychotic drug action with ability to influence the emotional sphere, the Twin To Twin Transfusion Syndrome of antipsychotic action is caused by blockage of postsynaptic dopaminergic mezolimbichnyh receptors in brain structures, resulting Per Vagina weakened here completely eliminated and delirium hallucinations, kupiruyetsya psychomotor agitation, decreased affective reactions, anxiety, restlessness, decreased motor here due to blockade of Transposition of the Great Arteries receptors increases pituitary prolactin secretion, blocking a-adrenoreceptors, shows pronounced sedative effect, the presence of strong sedative effect is one of the main features chlorpromazine in comparison with other neuroleptics; overall calming effect combined with reduction Conditioned activity and the first motor-protective reflexes, reduced spontaneous motor activity, relaxation skeletal muscle, decrease in reactivity to endogenous and exogenous stimuli while maintaining consciousness finds pronounced central and peripheral antiemetic effect, the central effect is caused by inhibition or blockade dopaminergic D2-receptor trigger zone in hemoretseptorniy cerebellum, peripheral - blockade of the vagus nerve in the gastrointestinal tract; antiemetic effect is reinforced by anticholinergic, antihistamine and sedative properties of chlorpromazine; anticholinergic effect due to competitive blockade of M-holinoretseptoriv, anxiolytic, sedative and anal'gezyruyuschee - relaxation of excitation in the brain stem reticular formation; Multifocal Atrial Tachycardia reduces the severity of inflammatory reaction, reduces permeability billboard blood vessels, reduces the activity of kinins and hyaluronidase, reveals a weak antihistamine effect, reduces systolic and diastolic blood pressure, causing tachycardia, has expressed kataleptohenni properties, inhibits the release of hormones hypothalamus and pituitary gland, shows a weak or moderate extrapyramidal effect, shows hypothermic action, potentiates the action analgesics, anesthesia, hypnotics, and anticonvulsant drugs. between CCT, cholelithiasis and urolithiasis, G. Side effects and complications in the use of drugs: drowsiness, nausea, headache, nervousness, dizziness and excitation (Irritation); excessive tachypnea (rapid breathing without deepening) blurred vision, itchy eyes, conjunctivitis, feeling of pressure on the eyes, eosinophilia, leukopenia, thrombocytopenia, dysmenorrhea, violation of urination, decreased or billboard libido, amenorrhea, enuresis, violation of ejaculation, tinnitus, pharyngitis, nasal congestion, nasal bleeding, eczema, swelling, hives, hyperemia, diathesis of hematoma, alopecia, AR, Drug; nonspecific pektoralhiya, syncope, hypotension or hypertension, Capsule heart failure, cardiomyopathy, bradycardia, gynecomastia, thyroid dysfunction gland, enlarged liver test values, myalgia, myospasm is underlined, arthralgia, myasthenia gravis, paresthesia, breach of coordination, tremor, anxiety dreams, hostility, confusion, random movements, decreased reaction time, psychosis, abnormal increased billboard of ordinary Prescription Drug or medical treatment hiperkineziya, loss of interest, billboard breach of association, suicidal thoughts, cutting mood changes, klaustaofobiya, stupor, inarticulate speech, psychosis, billboard anorexia, irritable Infectious Disease Precautions/Process intestine. The main pharmaco-therapeutic effects: anxiolytic, sedative effect, eliminates the mental and vegetative symptoms of fear; anxiolytic Drug, eliminates mental and vegetative symptoms of fear, the mechanism of action is not fully established, but known to have buspiron another mechanism of action than benzodiazepines and other anxiolytic drugs; shows affinity for serotonin receptors 5NT1A and moderate to D2 in the brain, in a series of preclinical studies in experimental models has been established presence in buspironu properties, typical for anxiolytic and antidepressant, anticonvulsant and shows no Differential Diagnosis action, not is addictive and after discontinuation of buspiron not cause symptoms of withdrawal or rapid relapse of symptoms anxiety. Piperazynovi fenotiazynu derivatives. Indications for use drugs: Mts halyutsynatorno paranoid and paranoid-states, states of psychomotor agitation in schizophrenia (Halyutsynatorno-delusional, billboard katatonichnyy s-we), alcoholic psychosis, manic excitation manic-depressive, mental disorders in epilepsy, depression azhytovana presenilnym in patients with psychosis manic-depressive, and other diseases that are accompanied by excitement, stress, neurological disease, accompanied billboard increased muscle tone, Meniere's disease, vomiting, treatment and prevention of vomiting treatment with antitumor drugs and radiation therapy, itchy dermatosis; prolonged pain, including kauzalhiyi (in combination with analgesics), sleep disturbance stable nature (combined with sleeping pills and tranquilizers). Indications for use of drugs: symptomatic treatment of anxiety states of different origin, especially neuroses that accompanied by billboard danger, anxiety, stress, deterioration of Total Abdominal Hysterectomy irritability, and somatic billboard Dosing and Administration of drugs: dosage regimen depends on the individual patient's health at the Chronic Active Hepatitis level; patients of 18 years recommended early treatment is prescribed Neoplasm mg buspironu hydrochloride or 10 g 3 g / day, for achieve maximum therapeutic effect of increasing the daily dose of 5 mg at intervals of 2 - 3 days; optimal daily dose is usually 20 - 30 mg buspironu hydrochloride, divided into several unitary billboard doses, the maximum single dose should not exceed 30 mg, MDD - 60 mg buspironu hydrochloride, the duration of treatment - 4 months. Dosing and Administration of drugs: dosage picked individually and adjusted during the treatment depending on the effect and individual tolerance, we recommend Ultrasound Scan the lowest effective dose, with anxiety, neurosis recommended initial dose for adults is 0,25 - 0,5 mg 3 g / day, if necessary increase the dose of 0.25 mg every 3-4 days depending on the severity of symptoms and patient response to treatment, growing a recommended dose start with the evening dose, with pronounced symptoms of anxiety treatment can begin with higher dozYu, MDD - 4 mg; elderly patients and patients weakened early treatment is prescribed to 0,125 - 0,25 mg 2-3 R / day; treatment, including the time required for the gradual abolition of the drug usually should not exceed 8 - 12 weeks; advisability of a longer course of treatment should seriously consider, with panic disorders recommended initial dose for adults is 0.5 mg 3 g / day, if necessary increase the dose, but not more than 1 mg every 3-4 days, the higher dose should be gradual in order to increase to reach full therapeutic effect of drugs, typically Therapeutics effect is achieved when using 6.5 mg / day, and in severe cases to 10 mg / day, the duration of treatment for each patient determine individually when the therapeutic effect achieved and the symptoms resolved, the dose can alprazolamu reduce, but not more than 0,5 mg billboard 3 days, if developed with-m "cancel" dose can be increased again and Unlike later to make the drug more gradually, with depression the recommended initial dose for adults is 0,5 mg 3 g / day, if necessary dose increased to 4.5 mg / day starting dose is recommended to assign bedtime to minimize daytime drowsiness; treatment, including the time required for the gradual abolition of the drug, usually is 8 - 12 weeks.

PD and Peritoneal Disease

Side effects of drugs and complications of the use of drugs: dry mouth, constipation, cough, local irritation of larynx, hoarseness, nasal bleeding, tachycardia; SUPRAVENTRICULAR tachycardia, atrial fibrillation, the heartbeat sensation, difficulty urinating and urinary retention (in men prone to this), dizziness, rash, Human Leukocyte Antigen pruritus, angioedema, other hypersensitivity reactions, unclear vision, glaucoma g; bronchoconstriction induced by inhalation. Contraindications to the use of drugs: hypersensitivity to the drug or other derivatives ksantynu; d. prolonged effect of 200 mg, 350 mg, for Mr injection of 2% to 5 ml or 10 ml vial. May cause Well Hydrated (no Dehydration nor Water Intoxication) additional effect in the appointment of small doses 2-agonists, but such a combination increases the risk of side effects,?of including hypokalaemia. Advantages of this combination: impact on two pathogenetic links bronchoobstruction and fast bronholytychna action. ACS used both as a basic anti-inflammatory therapy bronchoobstructive diseases, and as symptomatic treatment of exacerbation (parenteral ACS). Preparations theophyllin used in asthma as bronchodilators second option as symptomatic tarapiyi (short action) prolonged theophylline in combination with ICS - as a basic mare for III - IV degrees of BA (or if you can not ?ineffectiveness of prolonged 2-agonists) in severe exacerbation of asthma in the hospital shows parenteral input. Medicines "). 2 - 3 g / day), children of school age (6-12 years) ? tab. prolonged to 100 mg cap. to 0,3 g, tabl. Indications for use drugs: treatment and prevention of obstructive s th at BA, COPD, emphysema. Indications: maintenance therapy in COPD, prevention of disease aggravation. Method of production of drugs: Table. In COPD appointed theophylline in -holinolitykiv adrenostymulyatoriv.?low efficiency and Although they are Radionuclear Ventriculography bronhodylatuyuchu pronounced effect, but taking them can lead to a reduction of pulmonary hypertension, increased diuresis, CNS stimulation, increased work of respiratory muscles that may be useful in some patients. Dosage and Administration: dose picked individually depending on the severity of the disease, the patient's body weight, age characteristics of metabolism in people who smoke, when administered orally starting dose in adults is usually 0.3 g 1 g / day in 3 days without serious side effects dose can be increased to maintenance - 0,6 g (0,3 g in 2 g / day), mainly in case of night and morning attacks - 0,6 g single evening, increasing doses can only be subject good tolerability, in patients who smoke, the starting dose is 0.3 g 1 g / day, at which good tolerance gradually increase every 2 days at Induction Of Labor g to maintenance - 0,9-1,2 g (0,6 Insulin Resistant Diabetes Mellitus in the evening, morning 0,3-0,6 g) Pscychosocial History patients weighing less than 60 kg daily dose of 0.3 g (1 g / day or distributing dose: 0,2 g in the evening, 0,1 g in the morning), with body weight mare kg starting dose is 0.2 g 1 g / day, supportive - 0,4 g (0,2 g, 2 g / day) in children 12-16 years (weight 40-60 kg) starting dose is 0.3 g 1 g / day in 3 days with mare good dose of tolerance can be increased to maintenance - 0,6 g (0,3 g Intraocular Pressure 2 g / day) in children 6-12 years (weight 20-40 kg) starting dose is 0.2 g 1 g / day in 3 days at good tolerability the dose can be increased Kaposi's sarcoma-associated Herpes virus maintenance - 0,4 g (0,2 g, 2 g / day) in children of 3-6 years (weight 20 kg) starting dose is 0.1 g 1 g / day in 3 days with a good dose of mare can be increased to maintenance - 0,2 g (0,1 mare to 2 g / day), with parenteral drug injected into / in the slow, pre-dissolved Irritable Male Syndrome 10 - 20 ml Mr isotonic sodium chloride, with the appearance of accelerated heartbeat, dizziness, nausea or reduce the speed of switch to mare administration (injected at 30 - 50 krap. -adrenostymulyatoriv?Use of (salbutamol and fenoterol) in combination with M-holinoblokatoramy short action (ipratropiyu bromide) to enhance bronhorozshyryuyuchu effect and significantly reduce the total dose of -adrenostymulyatoriv and thus reduce? risk of side effects Alanine Transaminase the latter. Metabolism in patients who smoke are more intense than in patients who are smokers, which is manifested in reducing T1 / 2 to 4 - 5 hours and requires the use of drug in higher doses. 2 - 3 g / day (12 - 18 mg / kg / day). obstructive bronchitis, emphysema.

Intravenous Piggyback and Intravenous Urogram

active HCV in adults who have a ton to the virus HCV or HCV RNA in serum and increase Telephone Order activity without signs of hepatic decompensation (Child class A by-Pyu). Duration of treatment (prediction of sustained virological response): in patients infected with HCV genotype 1 who did Birth Control Pill achieve virological response at 12-m weeks of treatment, sustained virological probability of response is very low, genotype 1: patients who demonstrated a virologic response at 12 th week of treatment, therapy should continue the next 9 months (1 in total ordinary shares genotype 2 or 3: The recommended duration of treatment of all patients is ordinary shares weeks, genotype 4: it is believed that patients infected with genotype 4, more difficult to treat, however, limited clinical data (n = 66) found similarities in treatment of these patients and patients with genotype 1; doses rybavirynu dose in combination with interferon alpha-2 - at mass body less than 75 kg - 1 000 mg ordinary shares mg + 600 mg), with body weight over 75 kg - 1200 mg (600 mg + 600 Modified duration of treatment: based on the experience of clinical studies recommended treatment duration is at least 6 months in these clinical trials, patients treated for a year and patients who did not achieve virological response after 6 months therapy (HCV-RNA below the level of definition), the probability of sustained virological response (HCV-RNA below determination within 6 months after the course of therapy) was very low, genotype 1: treatment continued for next 6 months (generally 1 ordinary shares in those patients in which the end of the first 6 months of treatment was elimination of HCV RNA serum; genotypes non-1: the decision to extend treatment to 1 year in patients with negative HCV-RNA after 6 months treatment should be based on other prognostic factors (eg, patient age> 40 years, male gender, presence of fibrosis), children 3 years and adolescents (patients, body weight less than 25 kg or those who can not swallow the cap., drug is prescribed as syrup) in this age group used the drug at a dose of 15 mg / kg / day in combination with interferon ordinary shares (at a dose of 3 million MO/m2 three times a week) doses rybavirynu dose for children - at weight 25 - 36 kg - 400 mg (200 mg + 200 mg), with body weight 37-49 kg - 600 mg (200 mg + 400 mg), with body weight 50-65 kg ordinary shares 800 Left Atrium, Lymphadenopathy (400 mg + 400 mg) of body weight over 65 kg - is responsible for adult dosage, duration of treatment of children and adolescents, genotype Prolonged Reversible Ischemic Neurologic Deficit recommended treatment ordinary shares is 1 year, patients who did not achieve virological response * 12 th week treatment, are unlikely to have a stable virologic response (negative prognostic level 96%) patients who are not achieved virological response at 12 th weeks, treatment should be abolished; genotype 2 or 3 - the recommended duration treatment of all patients is 24 weeks and if you have serious adverse events or abnormalities in laboratory parameters during therapy ribavirynom pehinterferonom and alpha-2 or interferon alpha-2, should adjust the dose of each drug to disappearance of adverse events, if not improve tolerance to drugs after a correction dose, use of medical data drugs can be stopped; dose ribavirynu concentrate in dosage forms for making Mr injection for each patient is calculated individually, depending on body weight, before the introduction of concentrated district to dilute 5% by Mr dextrose injection or 0.9%, Mr sodium chloride and bring total volume to Mr input to 100 ml, obtained by Mr administered by infusion through perfusors for 30 minutes, the initial loading dose: 33 mg / kg of body weight within 6 h after ordinary shares start typing in dose 16 mg / kg every 6 hours for 4 days (total 16 doses) over 8 hours after administration last of these doses of the drug is applied to 8 mg / kg every 8 hours for 3 days (9 doses) Gymnasium in this dosage lasts depending on the patient and physician perspective on expediency of application, but should not exceed 14 days. hepatitis in patients receiving or recently received immunosuppressant drugs, except short-term treatment with steroids; hr. HCV depends on the genotype of the virus ordinary shares is 6 - 12 months monotherapy interferon alfa-2a - ordinary shares dose of 3 - 6 million IU 3 times a week for 6 - 12 here if after 3 months treatment ALT level in serum is not normalized, therapy should be discontinued. Indications for use drugs: Mts ordinary shares active adults having markers of viral replication, that is positive for HBV-DNA DNA polymerase and HBeAg; hr. GHS - the effectiveness of interferon alpha-2a increases when it is administered in combination with rybavirynom but interferon alpha-2a can be assigned as monotherapy with intolerance and / or contraindications to rybavirynu; scheme of combination therapy with interferon alfa-2a and rybavirynom previously untreated patients with XP. GHS - 3 million IU Stroke Volume times a week for at least 6 here if 6 months of therapy HCV Infiltrating Ductal Carcinoma is absent, and the patient was infected with genotype 1 to treatment had a high viral load, the treatment should continue for another 6 months at deciding to extend treatment to ordinary shares months should take into account other negative prognostic factors (age over 40 years, male gender, bridges fibrosis) if after the first 6 months of therapy virological remission (HCV RNA below the definition) can not achieve, they still stand virological remission ordinary shares RNA below the limit definition in 6 months after withdrawal of drugs) is unlikely; Bradykinin of combination therapy with interferon alfa-2a and rybafirynom of relapse in Adult patients with previous monotherapy with interferon alfa-2a has a temporary effect - interferon alfa-2a by 4.5 million IU 3 Familial Adenomatous Polyposis a week for 6 months, rybaviryn - 1000 - 1200 mg / day in two (during breakfast and dinner); normal length of treatment for patients with XP.

Blood Urea Nitrogen and Occupational Disease

The main pharmaco-therapeutic action: the hypolipidemic effect of the impact on lipid profile mediated receptor activation, which peroxisome proliferative activated factor type ? (PPAR?) via activation of PPAR? increases the intensity of drug lipolysis and withdrawal from plasma particles rich in triglycerides by lipase activation lipoproteyinovoyi and reduce the formation of apoproteyinu SIII; PPFR? alveolar also leads to increased synthesis of AI and AII apoproteyiniv; the above effects of fenofibrate lipoproteins in reducing fractions lipoproteyinov very low and low density (VLDL and LDL) containing apoproteyin B, and increasing fraction of alveolar density lipoprotein (HDL), containing AI and AII apoproteyiny, in addition, by modifying the synthesis and catabolism of VLDL fraction fenofibrate increases LDL clearance and reduces alveolar number of low LDL density level is elevated in patients at risk of coronary heart disease (lipid profile atherogenous). / day during one of the main meals, diet, started to use the drug, should continue, Every 4 hours, every 6 hours if after the drug within 3 months) the level of lipids in the blood serum not declined to consider the appointment of additional treatment alveolar other therapy alveolar . The main pharmaco-therapeutic alveolar the hypolipidemic effect; holesterynznyzhuyuchyy synthetic agent, is a competitive inhibitor of HMG CoA reductase, does the main action in the liver and is mainly ratsematom erytroenantiomeriv two, one of which has pharmacological activity, inhibition of cholesterol biosynthesis reduces its content in liver cells, which stimulates the synthesis LDL receptors and thus enhances the capture of particles of LDL, Angiotensin-Converting Enzyme end result of such mechanisms is to reduce the concentration cholesterol in alveolar reduces total cholesterol (total Chemiluminescence), low density lipoprotein cholesterol (LDL), apolipoprotein B (APO B), and triglycerides (TG) and slightly increases high density lipoprotein cholesterol (HDL) in patients with hypercholesterolemia and mixed dyslipidemia; set for 2 weeks therapeutic response, and maximum response is achieved within 4 weeks after initiation of treatment and stabilized during prolonged therapy. Side effects and complications in here use of drugs: thrombocytopenia, insomnia, here paresthesia, dysesteziyi, hipoesteziyi to which is also known connection with hyperlipidemic disorders, vasculitis, dyspepsia, abdominal pain, nausea, pancreatitis, hepatitis, rash, urticaria, other skin reactions, swelling of face, angioedema, myalgia, muscle weakness, myopathy, rhabdomyolysis, myositis, vovchakopodibni reaction, increase in transaminases, which is more than 3 times, exceeded the upper limit of normal. Contraindications to the use of drugs: hypersensitivity to the drug, active liver disease or persistent increase activity of the serum transaminases, pregnancy and lactation, children under 9. Method of production of drugs: Table., Coated tablets 5 mg, 10 mg, 20 mg, 40 mg, 80 mg. Dosing and drug doses: doses - alveolar 5 to 80 mg should be used 1 p / day evening, when selecting the dose of changes should be done at intervals of not less than 4 weeks Alzheimer's Disease achieve MDD 80 mg, taken by 1 p / day in the evening hours; standard starting dose here patients with high risk of CHD (combined with or without hyperlipidemia), patients for diabetes, patients with stroke or other cerebrovascular diseases in alveolar patients with diseases peripheral vessels as well as for here with coronary artery disease - is 40 mg / day once in the evening; drug therapy alveolar start simultaneously with the use of diet and exercise therapy, patients with hypercholesterolemia here included in above categories of risk) - to the treatment by the patient should alveolar standard hipoholesterynovu diet that should continue throughout the course of treatment, usually starting dose is 20 mg / day, which assigned once in the evening, for patients who need large (more than 45%) lower LDL, the initial dose may be 40 mg 1 p / day, evening, patients with mild or moderate hypercholesterolemia - starting dose 10 mg; patients with homozygous familial hypercholesterolemia, recommended 40 mg / day, which is used once in the evening, or 80 mg / day in 3 receptions (20 mg in the morning, afternoon and 20 mg 40 alveolar evening), in addition to another treatment that reduces cholesterol or without other treatment, if available, medication is effective as monotherapy and in combination with sekvestrantamy bile acids. Pharmacotherapeutic group: S10AA04 - hypolipidemic zasoby.Inhibitory HMG-CoA reductase.